CANCER 2026
Chair: Richard Lock
Mechanistic insights into how venetoclax-based therapy durably eradicates NPM1 mutated clones in acute myeloid leukaemia (#101)
5:10 PM
Unravelling intra-tumor phenotypic heterogeneity by single cell analysis in colorectal cancer organoids (#102)
5:13 PM
Linking cell fate determination in the embryonic forebrain to Diffuse Midline Glioma (#103)
5:16 PM
Targeting the non-canonical NF-kB pathway using the first-in-class IKKα inhibitor SU1644: An innovative approach to combat inflammation and overcome immunosuppression in advanced prostate cancer (#104)
5:19 PM
Targeting ICOS to improve breast cancer immunotherapy (#105)
5:22 PM
Kap1 maintains the hormone response of the mammary gland (#106)
5:25 PM